Welcome to our dedicated page for Immunovant news (Ticker: IMVT), a resource for investors and traders seeking the latest updates and insights on Immunovant stock.
Immunovant, Inc. reports recurring developments from a clinical-stage immunology business focused on anti-FcRn therapies for autoimmune diseases. Its news flow centers on IMVT-1402, a potential neonatal Fc receptor inhibitor, and batoclimab, with updates across Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis, Sjögren’s disease, cutaneous lupus erythematosus and thyroid eye disease.
Company updates also cover quarterly operating results, research and development spending, trial design and clinical-study results, safety observations, cash runway, financing activity and shareholder voting matters. Because Immunovant operates in a single research, development and manufacturing segment, recurring disclosures are closely tied to clinical execution, product-candidate manufacturing and capital resources for autoimmune disease programs.
Immunovant (Nasdaq: IMVT) will report financial results for the fourth quarter and fiscal year ended March 31, 2026 and provide a business update on Wednesday, May 20, 2026 at 8:00 a.m. ET. Access details and the archived webcast will be available on Immunovant’s investor website.
Immunovant (Nasdaq: IMVT) reported topline results from two Phase 3 studies of batoclimab in active, moderate-to-severe thyroid eye disease (TED) on April 2, 2026. Both studies failed to meet the prespecified primary endpoint of ≥2mm proptosis responder rate at Week 24.
Safety was consistent with prior findings and no new safety signals were identified. Patients showed greater proptosis improvement after the initial 12-week high-dose period versus the subsequent 12-week low-dose period. A hyperthyroid subset had thyroid hormone normalization rates similar to prior Phase 2 Graves’ disease data. Immunovant will review batoclimab with partner HanAll and advances IMVT-1402 with topline Graves’ data expected in 2027.
Immunovant (Nasdaq: IMVT) reported clinical and corporate updates and Q3 fiscal results for the period ended December 31, 2025. Key points: IMVT-1402 D2T RA trial is fully enrolled with topline data expected in H2 2026, and CLE topline data also expected in H2 2026.
The company completed an underwritten financing that raised approximately $550 million, and held $994.5 million in cash and equivalents as of December 31, 2025, supporting runway toward a potential GD launch. Multiple IMVT-1402 registrational programs remain on track.
Immunovant (Nasdaq: IMVT) will report financial results for the third quarter ended December 31, 2025 and provide a business update on Friday, February 6, 2026 at 8:00 a.m. ET. Investors can access a conference call (phone registration required) hosted with Roivant (Nasdaq: ROIV) and a live webcast. Presentation materials and a webcast archive will be available in the Investors "News & Events" section of Immunovant's website after the call.
Immunovant (Nasdaq: IMVT) priced an underwritten common stock offering to raise approximately $550 million of gross proceeds by selling 26.2 million shares at $21.00 per share. The company said existing cash plus proceeds are expected to fund operating expenses and capital expenditures through a potential commercial launch of IMVT-1402 for Graves’ disease.
Roivant Sciences, the controlling stockholder, agreed to purchase shares. The offering is expected to close on or about December 12, 2025, subject to customary closing conditions, with Leerink Partners as sole underwriter.
Immunovant (Nasdaq: IMVT) reported Q2 results for the period ended September 30, 2025, and provided clinical program updates.
Key points: cash and cash equivalents $521.9 million (runway through the Graves’ disease readout expected in 2027); an uncontrolled Graves’ disease study of IMVT-1402 showed a potentially disease-modifying six‑month off‑treatment outcome; IMVT-1402 development continues across GD, MG, CIDP, D2T RA and Sjögren’s with multiple readouts in 2026–2027. Financials: Q2 R&D $114.2M, Q2 net loss $126.5M ($0.73/sh), six‑month net loss $247.1M ($1.43/sh).
Immunovant (Nasdaq: IMVT) will report financial results for the second quarter ended September 30, 2025 and provide a business update on Monday, November 10, 2025 at 8:00 a.m. ET.
The company said investors can access the Roivant (Nasdaq: ROIV) conference call by phone after registering online and can view the presentation and live webcast via the Investors > News & Events section at https://www.immunovant.com/investors/news-events/ir-calendar. An archived webcast will be available on Immunovant’s website after the call.
Immunovant (NASDAQ: IMVT) has announced groundbreaking six-month remission data for its Graves' disease treatment. In a proof-of-concept study, ~80% (17/21) of patients maintained normal thyroid function six months after stopping batoclimab treatment. Notably, ~50% (8/17) of responders achieved anti-thyroid drug (ATD) free remission.
The study evaluated batoclimab with a 24-week treatment period using a dose step-down protocol (680mg weekly for weeks 0-12, followed by 340mg weekly for weeks 12-24). The company is now advancing with two potentially registrational trials for its lead compound IMVT-1402, testing a 600mg dose for 52 weeks without step-down, with topline results expected in 2027.
Immunovant (Nasdaq: IMVT) announced significant progress in its clinical development programs and financial results for Q2 2025. The company initiated two potentially registrational studies in June 2025: one for IMVT-1402 in Graves' disease (GD) and another for Sjögren's disease (SjD).
The company maintains a strong financial position with $598.9 million in cash, providing runway through GD readout expected in 2027. R&D expenses increased to $101.2 million, up from $75.5 million year-over-year, while net loss widened to $120.6 million ($0.71 per share).
Key upcoming milestones include batoclimab GD remission data in September 2025, and multiple trial results expected in 2026-2027 across various indications including D2T RA, CLE, GD, and MG.